# EDGAR Filing Document

**Accession Number:** 0001716166
**File Stem:** 0001493152-25-020750
**Filing Date:** 2025-11
**Character Count:** 7476
**Document Hash:** cde0318227ecceb70443be62e80af377
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-020750.hdr.sgml**: 20251104

**ACCESSION NUMBER**: 0001493152-25-020750

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251104

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251104

**DATE AS OF CHANGE**: 20251104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vivos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001716166
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 813224056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39796
- **FILM NUMBER:** 251450396

**BUSINESS ADDRESS:**
- **STREET 1:** 7921 SOUTHPARK PLAZA,
- **STREET 2:** SUITE 210
- **CITY:** LITTLETON
- **STATE:** CO
- **ZIP:** 80120
- **BUSINESS PHONE:** (866)908-4867

**MAIL ADDRESS:**
- **STREET 1:** 7921 SOUTHPARK PLAZA,
- **STREET 2:** SUITE 210
- **CITY:** LITTLETON
- **STATE:** CO
- **ZIP:** 80120

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vivos BioTechnologies, Inc.
- **DATE OF NAME CHANGE:** 20170901

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 4, 2025**

**Vivos Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39796** | **81-3224056** |
| **(State or other jurisdiction** | **(Commission** | **(I.R.S. Employer** |
| **of incorporation)** | **File Number)** | **Identification No.)** |

---

**7921 Southpark Plaza, Suite 210**

**Littleton, Colorado 80120**

**(Address of principal executive offices) (Zip Code)**

**(866) 908-4867**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | VVOS | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On November 4, 2025, Vivos Therapeutics, Inc. (the "Company") conducted its 2025 annual meeting of stockholders (the "Annual Meeting"). The number of shares of common stock of the Company entitled to vote at the Annual Meeting was 7,504,807 shares outstanding as of the September 8, 2025 record date (the "Voting Stock"). No other shares of the Company's capital stock were entitled to vote at the Annual Meeting.

The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was approximately 4,968,728 shares of Voting Stock, constituting a quorum. At the Annual Meeting, the Company's stockholders:

&nbsp;&nbsp;&nbsp;&nbsp;(i) elected
 each of R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson (collectively, the
 "Director Nominees") to serve as directors on the Company's Board of Directors (the "Board") for a
 one-year term that expires at the 2026 Annual Meeting of Stockholders, or until their earlier death, resignation or removal and their
 successors are elected and qualified;

&nbsp;&nbsp;&nbsp;&nbsp;(ii) approved
 and adopted an amendment (the "Amendment") to the Company's 2024 Omnibus Equity Incentive Plan (the "2024
 Plan"); and

&nbsp;&nbsp;&nbsp;&nbsp;(iii) ratified
 the appointment of Baker Tilly US, LLP, the successor to Moss Adams LLP, as the Company's independent registered public accounting
 firm for the fiscal year ending December 31, 2025.

The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

***Proposal No. 1 - Election of Directors***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson were each elected as a director to serve for a one-year term that expires at the 2026 annual meeting of stockholders or until a successor is elected and qualified or until her or his earlier death, incapacity, removal or resignation. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Shares Voted For** | **Shares Withheld** | **Broker Non-Vote** |
| R. Kirk Huntsman | 2763108 | 208971 | 1996649 |
| Dr. Ralph Green | 2661653 | 310426 | 1996649 |
| Anja Krammer | 2741252 | 230827 | 1996649 |
| Mark Lindsay | 2780996 | 191083 | 1996649 |
| Leonard Sokolow | 2700161 | 271918 | 1996649 |
| Dr. Matthew Thompson | 2627358 | 344721 | 1996649 |

---

***Proposal No. 2 - Approval of the Amendment to the Company's 2024 Omnibus Equity Incentive Plan***

Approved and adopted the Amendment to the 2024 Plan. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted For** | **Shares Voted Against** | **Shares Abstaining** | **Broker Non-Vote** |
| 2453436 | 516368 | 2275 | 1996649 |

---

***Proposal No. 3 - Ratification of the appointment of independent registered public accounting firm***

Appointment by the Company's audit committee of Baker Tilly US, LLP, the successor to Moss Adams LLP, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Shares Voted For** | **Shares Voted Against** | **Shares Abstaining** | **Broker Non-Vote** |
| 4861139 | 102827 | 4762 | n/a |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **VIVOS THERAPEUTICS, INC.** | **VIVOS THERAPEUTICS, INC.** |
| Dated: November 4, 2025 | *By:* | */s/ Bradford Amman* |
|  | Name: | Bradford Amman |
|  | Title: | Chief Financial Officer |

---